Aptevo Therapeutics (APVO) Revenue (2015 - 2022)
Aptevo Therapeutics (APVO) posted Revenue of $3.1 million for Q1 2022, down 15.03% sequentially from $3.7 million in Q4 2021, and up 28.62% YoY from $2.4 million in Q1 2021.
Aptevo Therapeutics (APVO) Revenue (2015 - 2022) Analysis & Trends
Aptevo Therapeutics has reported Revenue for 8 years, with the latest figure at $3.1 million in Q1 2022.
- Quarterly Revenue rose 28.62% year-over-year to $3.1 million in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $3.1 million (down 74.67% YoY) and the FY2022 annual result came in at $3.1 million, down 74.67% from the prior year.
- Revenue fell to $3.1 million in Q1 2022 per APVO's latest filing, from $3.7 million in the prior quarter.
- Over five years, Revenue peaked at $16.7 million in Q3 2018 and troughed at $473000.0 in Q2 2020.
- A 5-year average of $5.6 million and a median of $3.7 million in 2021 frame the typical range for Revenue.
- The sharpest annual moves came in 2020 and 2021: Revenue tumbled 93.57% in 2020, then jumped 557.51% in 2021.
- Over 5 years, Revenue stood at $16.7 million in 2018, then sank by 45.99% to $9.0 million in 2019, then plunged by 73.72% to $2.4 million in 2020, then soared by 54.45% to $3.7 million in 2021, then retreated by 15.03% to $3.1 million in 2022.
- According to Business Quant data, Revenue over the past three periods registered $3.1 million, $3.7 million, and $3.1 million for Q1 2022, Q4 2021, and Q3 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Aptevo Therapeutics | 3.30 Mn | -6.50 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 3.11 Mn |
| Dec 31, 2021 | 3.67 Mn |
| Sep 30, 2021 | 3.10 Mn |
| Jun 30, 2021 | 3.11 Mn |
| Mar 31, 2021 | 2.42 Mn |
| Dec 31, 2020 | 2.37 Mn |
| Sep 30, 2020 | 1.46 Mn |
| Jun 30, 2020 | 473,000.00 |
| Dec 31, 2019 | 9.03 Mn |
| Sep 30, 2019 | 9.01 Mn |
| Jun 30, 2019 | 7.36 Mn |
| Mar 31, 2019 | 7.02 Mn |
| Sep 30, 2018 | 16.72 Mn |
| Jun 30, 2018 | 10.90 Mn |
| Mar 31, 2018 | 4.07 Mn |
| Sep 30, 2017 | 6.17 Mn |
| Jun 30, 2017 | 3.53 Mn |
| Mar 31, 2017 | 2.14 Mn |
| Dec 31, 2016 | 8.77 Mn |
| Sep 30, 2016 | 2.82 Mn |